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The most prominent perfluorochemicals 
(PFCs) in human samples are perfluorooctane 
sulfonate (PFOS), perfluorooctanoate (PFOA), 
and perfluorohexane sulfonate (PFHxS), yet 
the sources and pathways of human expo­
sure to these, and other PFCs are not well 
characterized. Perfluorinated acids are ubiqui­
tous in the global environment, owing to their 
long history of manufacture and resistance 
to biological and environmental degradation 
pathways. Specifically for PFOA, the manu­
facturing sources responsible for its presence 
in various environments are not well under­
stood, and future human exposure is there­
fore difficult to predict. There are two main 
manufacturing methods leading to PFOS and 
PFOA: electrochemical fluorination (ECF) 
and telomerization. The 3M Company man­
ufactured the bulk of PFOS (and higher­
  molecular­weight precursor materials), PFHxS, 
and PFOA by ECF until 2001, at which time 
they voluntarily phased out these chemistries. 
Nonetheless, PFOS and its precursors con­
tinue to be manufactured by other companies 
in Asia (Martin et al. 2010). Telomerization 
continues to be used to manufacture PFOA. 
ECF and telomerized PFOA can be readily 
distinguished analytically because ECF PFOA 
consists of a mix of linear and branched iso­
mers (Loveless et al. 2006; Reagen WKL, 
Jacoby CB, Purcell RG, Kestner TA, Payfer 
RM, et al., unpublished data), whereas 
telomerized PFOA is almost exclusively the 
linear isomer (Kissa 1994).
If humans are exposed predominantly 
to ECF sources of PFOS and PFOA, serum 
concentrations should be decreasing because 
of their phase­out. In fact, when the 3M 
Company stopped manufacturing PFOS 
and PFOA by its ECF technique, blood lev­
els of PFOS declined steadily in Americans. 
However, for PFOA the initial rate of decline 
was much less than anticipated (Olsen et al. 
2008), and the most recent data from the 
National Center of Health Statistics of 
the U.S. Centers for Disease Control and 
Prevention (Kato et al. 2011) indicate that 
serum PFOA did not decline between April 
2003 and August 2007 and may be increasing 
[see Supplemental Material, Figure 1 (http://
dx.doi.org/10.1289/ehp.1003265)]. This 
suggests that exposure to recently produced 
telomer sources of PFOA might be impor­
tant, but the relative importance of ECF­ 
and telomer­derived PFC exposures through 
different exposure pathways (e.g., diet, 
dust, water, air) is unknown. Nonetheless, 
the potential for telomer PFOA exposure is 
  recognized, and in 2006 a global stewardship 
program was implemented to reduce emis­
sions of this chemical [U.S. Environmental 
Protection Agency (EPA) 2006].
For many environmental chemicals, house 
dust can be a major source of exposure (Butte 
and Heinzow 2002), particularly for children 
(U.S. EPA 2008). For PFOS and PFOA, food 
is a major source of exposure, but house dust 
can also be important under scenarios of high 
dust ingestion (Bjorklund et al. 2009; Goosey 
and Harrad 2011; Haug et al. 2011; Shoeib 
et al. 2011; Tittlemier et al. 2007). Thus, it is 
important from a risk mitigation perspective 
to understand whether PFCs in house dust 
are from current or historical manufacturing 
sources. PFOS and PFOA have been meas­
ured in dust previously (Kato et al. 2009; 
Kubwabo et al. 2005), but isomer­specific 
PFC analytical methods (Benskin et al. 2007; 
Langlois and Oehme 2006) have not been 
used to determine the manufacturing origins 
of PFOA and other PFCs in house dust.
Loveless et al. (2006) demonstrated that 
linear ammonium PFOA was generally more 
toxic than branched PFOA, but the isomer­
specific toxicity of PFCs has not been exam­
ined because of the lack of available standards. 
Studies in rats and zebrafish show that PFOA 
and PFOS are developmental toxicants (Lau 
et al. 2004), and many human epidemiology 
studies are now emerging on the potential 
perinatal effects of PFCs. For example, some 
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Ba c k g r o u n d: Perfluorochemicals (PFCs) are detectable in the general population and in the 
human environment, including house dust. Sources are not well characterized, but isomer patterns 
should enable differentiation of historical and contemporary manufacturing sources. Isomer-specific 
maternal–fetal transfer of PFCs has not been examined despite known developmental toxicity of 
perfluorooctane sulfonate (PFOS) and perfluorooctanoate (PFOA) in rodents. 
oBjectives: We elucidated relative contributions of electrochemical (phased out in 2001) and 
telomer (contemporary) PFCs in dust and measured how transplacental transfer efficiency (TTE; 
based on a comparison of maternal and cord sera concentrations) is affected by perfluorinated chain 
length and isomer branching pattern.
Me t h o d s : We analyzed matching samples of house dust (n = 18), maternal sera (n = 20), and 
umbilical cord sera (n = 20) by isomer-specific high-performance liquid chromatography tandem 
mass spectrometry.
re s u l t s: PFOA isomer signatures revealed that telomer sources accounted for 0–95% of total 
PFOA in house dust (median, 31%). This may partly explain why serum PFOA concentrations are 
not declining in some countries despite the phase-out of electrochemical PFOA. TTE data indicate 
that total branched isomers crossed the placenta more efficiently than did linear isomers for both 
PFOS (p < 0.01) and PFOA (p = 0.02) and that placental transfer of branched isomers of PFOS 
increased as the branching point moved closer to the sulfonate (SO3
–) end of the molecule.
co n c l u s i o n s: Results suggest that humans are exposed to telomer PFOA, but larger studies that 
also account for dietary sources should be conducted. The exposure profile of PFOS and PFOA iso-
mers can differ between the mother and fetus—an important consideration for perinatal epidemiol-
ogy studies of PFCs.
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epidemiology studies have shown inverse 
associations between PFOA exposure and 
birth weight (Apelberg et al. 2007; Fei et al. 
2008), whereas others did not find an associa­
tion (Monroy et al. 2008; Nolan et al. 2009). 
Furthermore, other adverse human health 
effects associated with PFCs are being detected 
in both background (Nelson et al. 2010) and 
highly exposed populations (Steenland et al. 
2010). From a public health perspective, and 
recognizing that many PFCs occur as multiple 
isomers of unknown relative toxicity, it may 
be important to characterize the exact nature 
of PFC exposure to humans, including for the 
mother and the fetus.
Understanding the maternal–fetal trans­
mission of PFCs is necessary to clearly under­
stand the risks and mechanisms of human 
developmental toxicity. Of studies that have 
reported the maternal–fetal transfer of PFCs, 
Hanssen et al. (2010) produced the only study 
to examine branched isomers separately from 
linear isomers. However, individual branched 
isomers were not examined separately (i.e., 
total branched PFOS was compared with lin­
ear PFOS). Although we are beginning to 
understand the pharmacokinetic properties 
of specific branched PFCs in animal models 
(De Silva et al. 2009), no study has yet inves­
tigated isomer­specific PFC pharmacokinetics 
in humans. In an attempt to understand the 
transplacental transfer of PFCs (mainly PFOS 
and PFOA), multiple studies have tested 
maternal and umbilical cord blood samples 
from different populations (Fei et al. 2007; 
Fromme et al. 2010; Hanssen et al. 2010; 
Inoue et al. 2004; Kim et al. 2011; Midasch 
et al. 2007; Monroy et al. 2008; Needham 
et al. 2011). One consistent finding in all 
these studies is that cord serum has lower 
total PFOA and lower total PFOS than does 
maternal serum; however the isomer­specific 
transplacental transfer of the various branched 
isomers has not been examined despite evi­
dence that the placental transfer is greater for 
total branched PFOS isomers than for linear 
PFOS (Hanssen et al. 2010).
In the present study we collected dust from 
the homes of 20 pregnant women who also 
donated a blood sample at 15 weeks of gestation 
and a cord blood sample at delivery. We meas­
ured PFC concentrations and isomer profiles 
in all samples in an effort to identify sources of 
PFCs in house dust and to examine the isomer­
specific transfer of PFCs across the placenta.
Materials and Methods
Nomenclature and acronyms. For structural 
isomers, we use the nomenclature defined 
by Benskin et al. (2007). Using PFOS as 
an example, the following annotations are 
used to represent the structure of each isomer 
based on relative position of perfluoromethyl 
substitution: linear perfluorooctane sulfonate 
(n­PFOS), perfluoroisopropyl (iso­PFOS), 
5­perfluoromethyl (5m­PFOS), 4­perfluoro­
methyl (4m­PFOS), 3­perfluoromethyl 
(3m­PFOS), 1­perfluoromethyl (1m­PFOS), 
tert­perfluorobutyl (tb­PFOS), and sum of 
all dimethyl isomers (Σm2­PFOS). Except 
for n­PFOS, all of the above­mentioned iso­
mers are branched isomers [for structures, 
see Supplemental Material, Figure 2 (http://
dx.doi.org/10.1289/ehp.1003265)]. 
PFC chemical standards. The 3M 
Company donated ECF PFOS [30% 
branched and 70% linear, by 19F nuclear 
magnetic resonance (NMR)] and PFOA 
(22% branched and 78% linear, by 19F 
NMR) standards (Reagen WKL, Jacoby CB, 
Purcell RG, Kestner TA, Payfer RM, et al., 
unpublished data). All other PFC standards, 
including PFOS and PFOA isomer standards 
and linear mass­  labeled internal standards 
for perfluoro  butanoate, perfluorohexanoate 
(PFHxA), PFHxS, PFOA, perfluorononano­
ate (PFNA), PFOS, perfluoro  decanoate 
(PFDA), perfluoroundecanoate (PFUnA), 
and perfluorododecanoate (PFDoA), were 
obtained from Wellington Laboratories 
(Guelph, ON, Canada).
Blood collection. Samples (n = 20) analyzed 
in this study are a subset of the Chemicals, 
Health and Pregnancy (CHirP) cohort 
recruited in 2007–2008 in Vancouver (BC, 
Canada) (Webster et al. 2011). All participants 
provided informed consent. Laboratory per­
sonnel collected blood samples from pregnant 
volunteers in Vancouver at 15 weeks of gesta­
tion, and samples of cord blood (n = 20) were 
collected at delivery. After serum separation, 
all samples were stored at –80°C. Ethical clear­
ance was obtained from the research ethics 
boards of the University of British Columbia, 
the University of Alberta, Health Canada, and 
the three participating hospitals.
Serum preparation. The method of 
Kuklenyik et al. (2004) was adapted for 
the extraction of PFCs from serum using a 
Rapid Trace system (Caliper Life Sciences, 
Hopkinton, MA, USA). The solid­phase 
extraction cartridge (Oasis­HLB, Waters, 
Milford, MA, USA; 60 mg/3 mL) was condi­
tioned with 2 mL methanol followed by 2 mL 
of 0.1 M formic acid. Serum was prepared for 
extraction by mixing 3 mL of 0.1 M formic 
acid with 1.0 mL serum. After the addition of 
mass­labeled internal standards (10 ng each), 
the mixture was vortexed and sonicated for 
20 min. Prepared serum was added to the col­
umn and washed successively with 3 mL of 
0.1 M formic acid, 6 mL of 50% 0.1 M formic 
acid/50% methanol, and 1 mL of 1% ammo­
nium hydroxide. The cartridge was drained by 
vacuum, and PFCs were eluted with 1.0 mL of 
1% ammonium hydroxide in acetonitrile. The 
eluate was concentrated to 100 μL followed by 
the addition of 200 μL of 90% 20 mM acetic 
acid in 10% methanol. Method blanks con­
taining calf serum, a calf serum sample spiked 
at 0.5 ng/mL of each PFC, and a human serum 
sample spiked at 10 ng/mL were analyzed with 
the study samples.
Dust collection and extraction. Dust sam­
ples were also a subset of those collected for 
the larger CHirP study (Shoeib et al. 2011). 
At 20–24 weeks of gestation, participants 
donated a used vacuum cleaner bag from their 
vacuum cleaner, or we took grab samples 
from the participants’ bagless vacuum cleaners 
(n = 18). Samples were stored at –20°C, and 
before analysis a portion of each dust sample 
was sieved using a stainless­steel sieve (mesh 
size, 150 μm; VWR International, Montreal, 
QC, Canada). Sieved dust (0.1 g) was spiked 
with 3.3 ng mass­labeled internal standards; 
4 mL methanol was added, and the sample 
was vortexed for 5 min, sonicated for 1 hr, 
and centrifuged at 3,400 rpm for 10 min. A 
2­mL aliquot was reduced by evaporation to 
100 μL, and 200 μL of 20 mM acetic acid 
with 10% methanol was added before high­
performance liquid chromatography tandem 
mass spectrometry (HPLC­MS/MS).
Total PFC analysis. For total PFC con­
centrations, separation was by HPLC on a 
150­mm Synergi Hydro­RP C­18 col­
umn (Phenomenex, Torrance, CA, USA). 
Gradient elution at 600 μL/min used A 
[20 mM ammonium acetate (pH 4) in water] 
and B (methanol) mobile phases. Initial con­
ditions were 60% A for 1 min, ramped to 
20% A by 3 min, a 5­min hold, an increase to 
100% B by 8.5 min, and a hold until 14 min, 
at which time initial conditions were rees­
tablished. MS/MS data were collected on 
an Applied Biosystems API 3000 mass spec­
trometer (Applied Biosystems, Carlsbad, CA, 
USA) using electrospray ionization in nega­
tive­ion mode [for mean recoveries of total 
PFCs in serum and dust, see Supplemental 
Material, Table 1 (http://dx.doi.org/10.1289/
ehp.1003265)].
Isomer-specific PFC analysis. The isomer­
specific HPLC­MS/MS method was adapted 
from Benskin et al. (2007). Briefly, 3 μL of 
the same extracts analyzed for total PFCs was 
injected onto a FluoroSep RP Octyl column 
(ES Industries, West Berlin, NJ, USA). Flow 
rate was 200 μL/min, and starting conditions 
were 60% A (water adjusted to pH 4.0 with 
ammonium formate) and 40% B (methanol). 
Initial conditions were held for 0.3 min, then 
ramped to 64% B by 1.9 min; increased to 
66% B by 5.9 min, 70% B by 7.9 min, 78% 
B by 40 min, 88% B by 42 min and finally to 
100% B by 45 min; and held until 60 min. 
Mass spectral data were collected using a 
5000Q mass spectrometer (MDS Sciex, 
Concord, ON, Canada) equipped with an 
electrospray interface operating in negative­
ion mode. Chromatograms were recorded PFC isomer profiles in blood and dust
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by multiple reaction monitoring with 3–13 
transitions per analyte.
Quality control. Triplicate recovery exper­
iments were performed at two concentrations 
of native linear standards spiked to calf serum 
or dust [see Supplemental Material, Table 1 
(http://dx.doi.org/10.1289/ehp.1003265)]. 
There are no mass­labeled internal standards 
for branched PFOS or PFOA isomers, so a 
standard addition experiment was done in 
dust to rule out possible matrix effects on 
the measured isomer profiles. Additionally, 
a vacuuming experiment was done to check 
whether off­gassing during vacuuming may 
bias the dust isomer profile. The results of 
these two experiments clearly showed that 
matrix effects and off­gassing during vacuum­
ing were not a problem. The percent recov­
ery during serum extraction was similar for 
all PFOS and PFOA isomers, such that the 
extraction step had no effect on the resulting 
isomer profiles (Benskin et al. 2007).
Results and Discussion
Total PFC concentrations in house dust. All 
total PFCs, except for perfluorodecane sul­
fonate (PFDS), were log­normally distributed 
[Shapiro–Wilk test; for distributions, see 
Supplemental Material, Table 2 (http://dx.doi.
org/10.1289/ehp.1003265)]. The three major 
PFCs in all dust samples (n = 18) were PFOA, 
PFOS, and PFHxA, with similar median 
values of 38, 37, and 35 ng/g, respectively. 
However, PFHxS exceeded PFOS in four sam­
ples. This pattern, whereby PFOA, PFOS, and 
PFHxA were the dominant PFCs, is similar to 
results from Strynar and Lindstrom (2008), 
who monitored U.S. house dust collected in 
2001/2002 and found median PFOA, PFOS, 
and PFHxA concentrations of 142, 201, and 
54.2 ng/g, respectively. The higher concentra­
tions of PFOS and PFOA observed by Strynar 
and Lindstrom (2008) are understandable 
given that these dust samples were collected 
years earlier than in the present study, around 
the time of the phase­out of ECF C8 perfluo­
rocarbon chemistries, although sampling strat­
egy and geography may also have contributed 
to differences.
PFC isomer profiles in house dust. For 
PFOS, we detected six major branched iso­
mers in dust: 1m­, 3m­, 4m­, 5m­, iso­, and 
Σm2­PFOS. All the dust samples had PFOS 
isomer profiles that were very similar to the 
3M Company ECF standard of PFOS, with 
a mean (± SD) branched isomer content 
of 30 ± 2.7%, and relatively low variability 
among individual branched isomers in various 
samples [Supplemental Material, Figure 3A, 
Table 3 (http://dx.doi.org/10.1289/
ehp.1003265)]. This was not surprising given 
that the 3M Company produced the bulk of 
PFOS (Paul et al. 2009) and that the historical 
batch­to­batch variation of branched isomer 
content was small: 30 ± 0.8% branched PFOS 
in 18 lots over 20 years (Reagen WKL, Jacoby 
CB, Purcell RG, Kestner TA, Payfer RM, 
et al., unpublished data).
Unlike PFOS, PFOA isomer profiles in 
dust were often substantially different from 
the 3M ECF PFOA standard. Although the 
relative profile among individual branched 
PFOA isomers was consistent among dust 
samples [Supplemental Material, Figure 3B, 
Table 3 (http://dx.doi.org/10.1289/
ehp.1003265)], we observed an excess signal 
of linear PFOA in many of the samples com­
pared with the 3M Company ECF standard. 
Like 3M Company PFOS, batches of 3M 
Company PFOA also had a consistent isomer 
composition: 22 ± 1.2% branched isomers in 
18 lots over 20 years (Reagen WKL, Jacoby 
CB, Purcell RG, Kestner TA, Payfer RM, 
et al., unpublished data). Therefore, these 
observations suggest that a significant propor­
tion of PFOA in these house dust samples 
came from a manufacturing source that used 
telomerization instead of ECF. We calculated 
the   “percent telomer” PFOA in each dust 
sample from the excess signal of linear isomer 
in samples (m/z 413/369 transition) com­
pared with 3M Company ECF PFOA. The 
percent telomer ranged from 0 to 95%, with a 
median of 31%, among all samples (Figure 1). 
The presence of telomer PFOA in the human 
household environment may partly explain 
why total PFOA in serum has declined so 
slowly after the phase­out of ECF perfluo­
rooctyl chemistries by 3M Company in the 
United States [see Supplemental Material, 
Figure 1 (http://dx.doi.org/10.1289/
ehp.1003265)] (Olsen et al. 2008). However, 
telomer PFOA also may be present in food, 
and telomer PFOA precursors used in food 
packaging may be absorbed and biotrans­
formed to PFOA after ingestion (D’eon and 
Mabury 2011).
Isomer­specific chromatograms of house 
dust clearly indicate that other perfluoro­
carboxylates (i.e., PFCs with –CO2
– as a 
functional group) had only minor branched 
isomer content (data not shown). Authentic 
standards were not available for confirmation, 
so we identified peaks as branched isomers 
only when two characteristic MS/MS transi­
tions responded at the same retention time. 
Most perfluorocarboxylates other than PFOA 
appeared exclusively linear, but in a minority 
of dust samples PFNA had up to four minor 
branched isomers, whereas PFHxA, PFDA, 
PFUnA, and PFDoA each had up to two 
minor branched isomers. The manufacturing 
sources of these particular branched perfluoro­
carboxylates cannot be confirmed because of 
limited information on their manufacturing 
sources and a lack of reference materials, but 
they may be residuals from ECF manufactur­
ing of PFOS and PFOA. Perfluorosulfonates, 
such as PFDS, perfluoroheptane sulfonate, 
and PFHxS, are generally assumed to have 
been produced exclusively by ECF, and these 
all had major branched isomer content based 
on peak areas (data not shown). However, 
because reference materials were not available, 
we could not examine how closely they resem­
bled authentic ECF manufacturing sources.
Total PFCs in maternal and cord sera. 
Concentrations of total PFOS (n = 20), PFOA 
(n = 20), PFNA (n = 20), PFDA (n = 16), and 
PFHxS (n = 8) in maternal serum were always 
significantly higher (p < 0.01) than in cord 
serum, consistent with previous maternal–fetal 
transfer studies of PFOS and PFOA (Table 1). 
The major total PFCs in maternal and cord 
sera were PFOS, PFOA, PFHxS, and PFNA, 
similar to previous findings (Inoue et al. 2004; 
Midasch et al. 2007; Monroy et al. 2008). In 
the present study, the mean concentrations of 
PFOS, PFOA, PFHxS, PFNA, and PFDA in 
maternal serum (cord serum) were 5.5 (1.8), 
Figure 1. Percent telomer PFOA and total PFOA concentration in house dust samples (left to right, lowest 
to highest total PFOA concentration), by ID (identification number). 
aSample collected by mechanical sweeper instead of vacuum.
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1.8 (1.1), 1.7 (0.7), 0.9 (0.4), and 0.4 (0.1) 
ng/mL, respectively. We detected PFUnA, 
PFDoA, and perfluorotetradecanoate (PFTA) 
(detection limit, 0.1 ng/mL) in six, two, and 
three maternal samples, respectively, but in no 
cord samples.
We estimated transplacental transfer effi­
ciencies (TTEs) by dividing the PFC concen­
trations in cord serum at delivery by maternal 
serum concentration at 15 weeks of gestation 
for each mother–cord pair (Table 2). Mean 
TTEs were always < 1.0, indicating lower con­
centrations in cord serum than in maternal 
serum (all p < 0.01). Overall, the PFOS and 
PFOA TTEs were within the range reported 
in the literature. However, it is likely that our 
TTEs slightly underestimate actual TTE values 
because they do not reflect hematologic changes 
that occur later in pregnancy, including expan­
sion of total plasma volume (Whittaker et al. 
1996). Such an effect was shown by Monroy 
et al. (2008), who reported lower serum PFOS 
and PFOA levels in maternal serum samples 
collected at delivery versus 24th through 28th 
weeks of gestation, and by Fei et al. (2007), 
who reported that cord:maternal ratios based 
on maternal serum samples were higher when 
collected during the second trimester than dur­
ing the first trimester (Table 1). We used the 
data from Monroy et al. (2008) (see Table 1 
notes) to estimate time­of­delivery maternal 
serum concentrations, based on our 15­week 
data, but this had little effect on the resulting 
TTEs, and both adjusted and unadjusted TTE 
values were within the range of TTEs reported 
previously (Table 1).
A comparison of TTEs among the three 
major perfluoroalkyl carboxylates (PFOA, 
PFNA, and PFDA) suggests that the 
  longer­chain carboxylates were more efficiently 
blocked by the placental barrier (Figure 2A), 
consistent with the results of Kim et al. 
(2011). The same trend was also evident for 
the two major perfluorosulfonates (PFHxS 
and PFOS; Figure 2B). Overall, shorter­chain 
PFCs crossed the placenta more efficiently 
than did longer­chain PFCs, consistent with 
the findings of Needham et al. (2011).
PFC isomer profiles in maternal and cord 
sera. The percent branched content of total 
PFOS was consistently and significantly higher 
in cord serum than in corresponding maternal 
serum and dust samples (Figure 3). Branched 
PFOS isomers contributed 27–44% (median, 
36%) of total PFOS in maternal serum and 
36–54% (median, 46%) in cord serum. A 
paired t­test indicated statistically greater pro­
portions of branched PFOS in the cord serum 
(p < 0.01). Overall, all branched PFOS iso­
mers were transferred more efficiently (median 
TTEs of the different branched isomers, 
0.34–0.88) than was the linear isomer (median 
TTE, 0.30) (Table 2). This is similar to results 
of the Hanssen et al. (2010) study, which 
found a statistically greater relative abundance 
of linear PFOS in maternal serum than in cord 
serum relative to total branched PFOS isomers 
(p < 0.05 by Wilcoxon’s signed rank test).
Unlike Hanssen et al. (2010), who quanti­
fied total branched PFOS isomers together, 
we analyzed individual branched isomers, and 
results suggest a structure–activity relationship 
for TTE. Specifically, among the perfluorom­
ethyl PFOS branched isomers, TTE increased 
as the branching point moved closer to the 
sulfonate moiety: 1m > 3m > 4m ≈ 5m > iso 
(Figure 2C). In fact, for 1m­, 3m­, and par­
ticularly Σm2­PFOS, the concentrations were 
sometimes higher in cord serum than in cor­
responding maternal serum (resulting in maxi­
mum TTE values > 1.0), which was never the 
case for total PFOS or linear PFOS (Table 2).
Branched PFOA isomers contributed 
0.43–4.3% (mean, 1.9%) of total PFOA in 
maternal serum and 0.71–5.7% (mean, 2.2%) 
in cord serum. Such highly linear isomer pro­
files of PFOA in human serum have previ­
ously been reported (De Silva and Mabury 
2006), yet it is important to note that these 
cannot be used to quantitatively assess expo­
sure sources (i.e., telomer vs. electrochemi­
cal) because in animal models the branched 
isomers of PFOA are accumulated to a lesser 
extent than are linear PFOA (De Silva et al. 
2009). No structure–activity relationship was 
evident for PFOA isomers (Figure 2D), but 
a paired t­test indicated significantly higher 
total branched PFOA isomers in cord serum 
than in maternal serum (p = 0.02). In some 
cases, the concentrations of 5m­, 4m­, and 
Table 1. Summary of existing studies on maternal–fetal transfer of total PFOA and total PFOS.
Mean cord:maternal 
serum concentration 
(correlation coefficient)
Study Sampling year Location Sample size PFOA PFOS
Needham et al. 2011 2000 Faroe Islands 12 0.72 (0.91)a 0.34 (0.82)a
Kim et al. 2011 2007 Korea 20 0.69 (0.88)a 0.36 (0.50)b
Fromme et al. 2010 2007–2009 Germany 27 0.70 (0.94)b 0.30 (0.89)b
Hanssen et al. 2010 2005–2006 South Africa 58 0.71 (0.67)b 0.45 (0.88)b
Monroy et al. 2008 2004–2005 Canada 101 0.81 (0.88)a 0.45 (0.83)a
Midasch et al. 2007 2003 Germany 11 1.26 (0.72)b 0.60 (0.42)b
Fei et al. 2007 1996–2002 Denmark 50c 0.55 0.29
50d 0.68 (0.84)a 0.34 (0.72)a
Inoue et al. 2004 2003 Japan 15 0.32 (0.88)a
Present study 2007 Canada 20d 0.61 (0.63)b 0.33 (0.81)b
20e 0.71 (0.76)b 0.36 (0.81)b
aPearson correlation. bSpearman rank correlation. cMaternal serum was sampled in the first trimester. dMaternal serum 
was sampled in the second trimester. eTTE adjusted from 15 weeks to time of delivery (~ 40 weeks) using data from 
Monroy et al. (2008), whereby PFOS declined 10% and PFOA declined 12% between the 24th to 28th week and delivery.
Table 2. TTE calculated from cord:maternal serum concentrations. 
Compound
Arithmetic 
mean Median SD Minimum Maximum na
Total, linear, and branched PFOS
Total PFOS 0.33 0.31 0.09 0.20 0.53 20
n-PFOS 0.33 0.30 0.12 0.10 0.58 20
Iso- PFOS 0.36 0.34 0.14 0.09 0.60 20
5m-PFOS 0.53 0.52 0.18 0.25 0.93 20
5m-PFOS 0.53 0.52 0.18 0.25 0.93 20
4m-PFOS 0.55 0.52 0.19 0.20 0.85 20
3m-PFOS 0.67 0.68 0.23 0.21 1.12 20
1m-PFOS 0.87 0.88 0.23 0.36 1.24 20
Σm2-PFOS 0.84 0.78 0.37 0.22 1.72 20
Total, linear, and branched PFOA
Total PFOA 0.61 0.63 0.17 0.32 0.96 20
n-PFOA 0.62 0.61 0.20 0.26 1.00 20
Iso-PFOA 0.84 0.67 0.58 0.16 2.56 20
5m- PFOA 0.86 0.54 0.99 0.09 2.26 4
4m- PFOA 0.64 0.68 0.34 0.09 1.29 19
3m-PFOA 0.76 0.68 0.59 0.07 2.74 18
tb-PFOA 0.25 0.25 0.32 0.02 0.48 2
Other PFCs
Total PFNA 0.41 0.38 0.17 0.13 0.78 20
Total PFDA 0.34 0.23 0.25 0.00 1.10 16
Total PFHxS 0.41 0.38 0.12 0.29 0.56 8
Values < 1 indicate higher concentrations in maternal serum; > 1.0, higher concentrations in cord serum.
aNumber of maternal–cord pairs that were available for calculating TTE. When concentrations were nondetect in mater-
nal or cord samples, that pair was excluded in the analysis. Mean TTEs were always < 1.0, indicating lower concentra-
tions in the cord serum than maternal serum (all p < 0.01). Linear PFOS and PFOA are denoted as n-PFOS and n-PFOA 
respectively.PFC isomer profiles in blood and dust
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3m­PFOA were higher in the cord serum than 
in corresponding maternal serum (resulting in 
maximum TTE > 1.0), which was never the 
case for total PFOA or linear PFOA (Table 2).
Passive diffusion is often the mechanism 
by which chemicals cross the placental barrier 
(Syme et al. 2004), so the TTE of hydrophilic 
compounds is generally lower than for hydro­
phobic compounds (Van der Aa et al. 1998). 
Based on earlier elution in reverse­phase chro­
matography, branched PFOS isomers are 
anticipated to be more hydrophilic than lin­
ear PFOS, and short­chain carboxylates (e.g., 
PFOA) should be more hydrophilic than 
longer­chain carboxylates (e.g., PFNA and 
PFDA), so the present results are unexpected. 
However, perfluorinated acids are highly pro­
tein bound in serum (Jones et al. 2003), and 
the dynamics of protein binding are likely to 
influence TTE. For example, if the binding 
affinity of linear PFOS to maternal serum 
protein is higher than for branched PFOS iso­
mers, a higher free fraction of branched PFOS 
would be available to cross the placenta.
For the major PFCs in maternal serum, 
we examined whether the branched isomer 
content was correlated to the branched isomer 
content in the corresponding house dust sam­
ple. Although we did not observe a significant 
correlation between serum and dust branched 
isomer content for PFOS (Spearman correla­
tion coefficient = –0.10, p = 0.35) or PFHxS 
(Spearman correlation coefficient = –0.11, p = 
0.33), we found a borderline significant cor­
relation for PFOA (Spearman correlation coef­
ficient = 0.35, p = 0.08). However, we cannot 
confirm that dust was a source of branched 
PFOA isomers in these women, given the small 
sample size (n = 20) and the potential contri­
bution of other sources of exposure, including 
diet, water, and air (Haug et al. 2011).
In contrast with expectations, we observed 
a higher mean percentage of branched PFOS 
isomers in maternal serum [36%; 95% confi­
dence interval (CI): 33.6, 38.2%] than in his­
toric 3M Company ECF PFOS (30%; 95% 
CI: 29.3, 30.7%) (Reagen WKL, Jacoby CB, 
Purcell RG, Kestner TA, Payfer RM, et al., 
unpublished data) or in house dust samples 
(30%; 95% CI: 28.6, 31.3%). A paired t­test 
showed significantly higher branched PFOS 
content in maternal serum than in house dust 
(6% higher; 95% CI: 3.1, 8.9%; p < 0.001). 
Studies in rodents show that branched PFOS 
isomers are no more bioaccumulative than 
linear PFOS (De Silva et al. 2009), so it 
would seem pharmacokinetically impossible 
to accumulate > 30% branched PFOS iso­
mers if the only source of exposure was ECF 
PFOS. Nonetheless, Karrman et al. (2007) 
and Hanssen et al. (2010) also reported high 
proportions of branched PFOS isomers in 
human serum. Although it is possible that 
PFOS isomer pharmacokinetics in humans 
are opposite that in rats (De Silva et al. 
2009) or that some humans are exposed to 
an unusually high branched PFOS source 
in the diet, an alternative explanation is that 
a significant proportion of the PFOS body 
burden comes from metabolism of PFOS 
precursors. Benskin et al. (2009) demon­
strated that branched isomers of a PFOS 
precursor could be biotransformed at greater 
rates than the corresponding linear precur­
sor, and Haug et al. (2011) found a signifi­
cant association between PFOS precursors in 
air and increasing branched PFOS content 
of serum. In the present samples, maternal 
and cord serum PFOS concentrations were 
higher (p < 0.01 for maternal serum, p = 0.01 
for cord serum) when we detected N­methyl 
perfluorooctanesulfonamidoacetate (a PFOS 
precursor) in the same sample, but we found 
no significant association between total dust 
PFOS precursors and the branched PFOS 
content of serum (p = 0.47).
Study limitations. One limitation of 
this study is the relatively small sample size. 
Larger studies are recommended to elucidate 
the relative importance of ECF­ and telomer­
derived sources of PFCs to humans in other 
areas. The present study was not designed 
to test whether PFC signatures in dust were 
responsible for PFC signatures in maternal 
or cord serum; rather, it was an exploratory 
investigation of the variability of isomer 
profiles in dust to elucidate manufacturing 
sources, and of the variation of isomer profiles 
Figure 2. TTE distributions for different-chain-length perfluorocarboxylates (A) and perfluorosulfonates 
(B) and for linear and branched PFOS (C) and PFOA (D) isomers. The upper and lower bounds of the 
boxes indicate the 75th and 25th percentiles, respectively, and the horizontal lines within the boxes indi-
cate median values. The upper and lower limits of the whiskers indicate minimum and maximum values, 
respectively, and points above or below the whiskers indicate outlier values. In A, B, and D, the number 
attached to each outlier is the number of a specific sample.
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between maternal and cord samples to exam­
ine whether branched isomers crossed the pla­
centa to different extents.
A second limitation was that the time of 
sampling of pregnant women (15 weeks) was 
relatively early in the pregnancy, and it is not 
clear whether the isomer profile might have 
been different at time of delivery. For two 
women in our study we also analyzed 18­week 
serum samples, and total PFOS and individ­
ual PFOS isomers were not substantially dif­
ferent over these 3 weeks (data not shown). 
Although this is a narrow window of time, it 
is not an insignificant period because hemato­
logic indices change significantly beginning as 
early as the 7th week of pregnancy, including 
expansion of total blood plasma volume by 
16% between 12 and 20 weeks (Whittaker 
et al. 1996).
Conclusion
Both ECF and telomer manufacturing sources 
contributed to household dust PFOA concen­
trations in this exploratory study. Some homes 
with the highest PFOA dust concentrations 
had a near exclusive telomer PFOA signal, and 
such results may help explain why PFOA con­
tinues to be a major contaminant of human 
serum despite the ECF PFOA phase­out. 
Larger­scale studies that examine manufactur­
ing sources while simultaneously accounting 
for dietary pathways would be beneficial. It is 
recognized that such investigations are techni­
cally challenging because isomer profiles in 
biological samples (i.e., food) may bias source 
apportionment due to differential uptake of 
the various isomers. The TTE of PFCs was 
inversely related to chain length, and TTEs 
suggest that most branched PFOA and PFOS 
isomers crossed the placenta to a greater extent 
than the corresponding linear isomer. In some 
cases, minor PFOA and PFOS branched iso­
mers were more concentrated in cord serum 
than maternal serum, indicating that isomer­
specific analysis should be performed in future 
studies of PFCs and birth outcomes.
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